ClinicalTrials.gov
public full text
Public Domain
A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment
dementiamental-disordersneurocognitive-disordersneurodegenerative-diseasesparkinson-diseaseparkinson-s-disease
This study will evaluate the safety, tolerability, and potential effects on cognition of GRF6021, a plasma-derived product, administered as an intravenous (IV) infusion, to subjects with Parkinson's disease and cognitive impairment.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Study in Patients With Advanced Parkinson's Disease to Assess the Relative Bioavailability of Levodopa Administered as ND0612 Subcutaneous Infusion Versus Levodopa Administered as Carbidopa-Levodopa Enteral Suspension#838117
- A Study With an Increased Dose Step in Patients That Have Previously Received Placebo or sNN0031.#918970
- NINDS Parkinson's Disease Neuroprotection Trial of CoQ10 and GPI 1485#1138256
- MAD Study of NX210c#1369962
- Evaluation of the Containment Impact Linked to the Covid-19 Pandemic in a Population of Parkinson Patients#832733
Record · ID 1349973
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive